RE:RE:RE:'Won't find a more full pipeline for a company this size'There is the US$10 million upfront from the financing and a potential second US$10 million upon exercise of warrants that could be triggered in 2023 given the expected event horizon. Add payments from potential deals for xB3 and Q-Sphera and that can further support the cash runway through hard data catalysts. Midatech's CEO is hopeful for a deal with J&J on Q-Sphera in 2023. BTI's xB3 multi-product option with J&J expires in about 30 business days. In 2023 Biodexa could have validation from the world's largest healthcare company for xB3 and Q-Sphera and the scale to also develop these platforms itself as a therapeutics company. Midatech's CEO challenges anyone to find a biotech of Biodexa's size with the opportunities it has. The first patient in the glioblastoma trial, which targets a $5 billion opportunity appears to further strengthen the safety and tolerability profile of the drug Midatch has already used in two other Phase I clinical trials. The first two clinical trials led to remarkable survival data though in an underpowered trial.